LTC2152868I2 - Prokariotinės fenilalanino amonio liazės kompozicijos ir minėtų kompozicijų naudojimo būdai - Google Patents

Prokariotinės fenilalanino amonio liazės kompozicijos ir minėtų kompozicijų naudojimo būdai

Info

Publication number
LTC2152868I2
LTC2152868I2 LTPA2019517C LTPA2019517C LTC2152868I2 LT C2152868 I2 LTC2152868 I2 LT C2152868I2 LT PA2019517 C LTPA2019517 C LT PA2019517C LT PA2019517 C LTPA2019517 C LT PA2019517C LT C2152868 I2 LTC2152868 I2 LT C2152868I2
Authority
LT
Lithuania
Prior art keywords
compositions
methods
ammonium lyase
phenylalanine ammonium
prokaryotic phenylalanine
Prior art date
Application number
LTPA2019517C
Other languages
English (en)
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39868905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC2152868(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of LTPA2019517I1 publication Critical patent/LTPA2019517I1/lt
Publication of LTC2152868I2 publication Critical patent/LTC2152868I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LTPA2019517C 2007-05-25 2019-10-10 Prokariotinės fenilalanino amonio liazės kompozicijos ir minėtų kompozicijų naudojimo būdai LTC2152868I2 (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/807,227 US7534595B2 (en) 2006-06-12 2007-05-25 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
PCT/US2008/006661 WO2008153776A1 (en) 2007-05-25 2008-05-23 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions

Publications (2)

Publication Number Publication Date
LTPA2019517I1 LTPA2019517I1 (lt) 2019-10-25
LTC2152868I2 true LTC2152868I2 (lt) 2020-09-25

Family

ID=39868905

Family Applications (1)

Application Number Title Priority Date Filing Date
LTPA2019517C LTC2152868I2 (lt) 2007-05-25 2019-10-10 Prokariotinės fenilalanino amonio liazės kompozicijos ir minėtų kompozicijų naudojimo būdai

Country Status (29)

Country Link
US (1) US7534595B2 (lt)
EP (2) EP2657335A1 (lt)
JP (1) JP5670183B2 (lt)
KR (2) KR20150038753A (lt)
CN (1) CN101842482B (lt)
AR (2) AR066716A1 (lt)
AU (1) AU2008263190B2 (lt)
BR (1) BRPI0811267B8 (lt)
CA (1) CA2687450C (lt)
CL (1) CL2008001497A1 (lt)
CY (2) CY1116894T1 (lt)
DK (1) DK2152868T3 (lt)
EA (1) EA018443B1 (lt)
ES (1) ES2551315T3 (lt)
HR (1) HRP20151268T1 (lt)
HU (2) HUE025784T2 (lt)
IL (1) IL202132A (lt)
LT (1) LTC2152868I2 (lt)
LU (1) LUC00133I2 (lt)
MX (1) MX2009012453A (lt)
MY (1) MY151413A (lt)
NL (1) NL301011I2 (lt)
NO (1) NO2019037I1 (lt)
PE (1) PE20090315A1 (lt)
PL (1) PL2152868T3 (lt)
PT (1) PT2152868E (lt)
SI (1) SI2152868T1 (lt)
TW (1) TWI418633B (lt)
WO (1) WO2008153776A1 (lt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7560263B2 (en) 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2010014225A2 (en) * 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
ES2690542T3 (es) 2010-02-04 2018-11-21 Biomarin Pharmaceutical Inc. Método para purificar variantes de fenilalanina amoníaco-liasa procariotas
US20150246083A1 (en) * 2012-07-27 2015-09-03 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
SMT201900315T1 (it) 2013-04-18 2019-07-11 Codexis Inc Polipeptidi di fenilalanina ammoniaca liasi ingegnerizzati
EP3071515A2 (en) 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
HUE054471T2 (hu) 2014-04-01 2021-09-28 Rubius Therapeutics Inc Immunmodulációs módszerek és készítmények
EP3928787A1 (en) 2014-04-16 2021-12-29 Codexis, Inc. Engineered tyrosine ammonia lyase
FI3237621T3 (fi) 2014-12-22 2023-06-01 Codexis Inc Ihmisen alfa-galaktosidaasivariantteja
TWI899515B (zh) * 2015-08-04 2025-10-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
IL263801B2 (en) 2016-07-26 2024-01-01 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
WO2018043546A1 (ja) * 2016-08-30 2018-03-08 三菱ケミカル株式会社 変異型酵素の製造方法及び変異型アルコールアシルトランスフェラーゼ
CN106497905A (zh) * 2016-12-14 2017-03-15 江南大学 一株鱼腥藻来源的苯丙氨酸脱氨酶的突变体
CA3051262A1 (en) 2017-02-13 2018-08-16 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
CN107653275A (zh) * 2017-10-30 2018-02-02 安徽工程大学 D‑苯丙氨酸的制备方法
CN108004225B (zh) * 2017-12-19 2020-05-08 江南大学 一种成团泛菌来源的苯丙氨酸氨基变位酶的突变体
JP2021522811A (ja) 2018-05-09 2021-09-02 ビオマリン プハルマセウトイカル インコーポレイテッド フェニルケトン尿症の治療方法
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
WO2019241132A1 (en) * 2018-06-12 2019-12-19 Codexis, Inc. Engineered tyrosine ammonia lyase
US11198861B2 (en) * 2018-07-12 2021-12-14 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
AU2019397401A1 (en) 2018-12-14 2021-06-17 Codexis, Inc. Engineered tyrosine ammonia lyase
EP3898960A4 (en) 2018-12-20 2022-11-30 Codexis, Inc. VARIANTS OF HUMAN ALPHA GALACTOSIDASE
CN110456056A (zh) * 2019-07-22 2019-11-15 浙江大学 一种新生儿苯丙酮尿症无创筛查试纸的制备方法
MX2022002473A (es) 2019-08-30 2022-08-02 Codexis Inc Variantes de lipasa modificadas geneticamente.
WO2021127457A1 (en) 2019-12-20 2021-06-24 Codexis, Inc. Engineered acid alpha-glucosidase variants
CN116113691A (zh) 2020-02-04 2023-05-12 科德克希思公司 工程化亮氨酸脱羧酶
WO2021168060A1 (en) * 2020-02-19 2021-08-26 Trustees Of Tufts College Methods for engineering amino acid ammonia lyase enzymes and enzymes thereby obtained
AR122409A1 (es) 2020-04-03 2022-09-07 Biomarin Pharm Inc Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
AU2021331493A1 (en) 2020-08-28 2023-03-09 Codexis, Inc. Engineered amylase variants
EP4204554A4 (en) 2020-08-28 2024-08-21 Codexis, Inc. MODIFIED PROTEASE VARIANTS
WO2022245924A1 (en) * 2021-05-19 2022-11-24 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects
TW202313969A (zh) 2021-05-21 2023-04-01 美商克迪科思股份有限公司 經工程化的甲硫胺酸γ解離酶變異體
US20250000957A1 (en) * 2021-09-16 2025-01-02 Arcturus Therapeutics, Inc. Compositions and methods for treating phenylketonuria
WO2023077169A2 (en) 2021-11-01 2023-05-04 Codexis, Inc. Engineered leucine decarboxylases
CN117417925A (zh) * 2022-07-18 2024-01-19 浙江泽科塔生物医药有限公司 Pal变体、包含该pal变体的药物组合物以及用于制备该pal变体的方法
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
CN116478975B (zh) * 2023-06-16 2023-09-01 苏州优信合生技术有限公司 高活性苯丙氨酸解氨酶突变体及其表达菌株
TW202521161A (zh) 2023-11-17 2025-06-01 美商拜奧馬林製藥公司 苯丙胺酸解氨酶與ｐｏｅｇｍａ之結合物及其使用方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
JP2930723B2 (ja) 1992-11-19 1999-08-03 アンティキャンサー インコーポレーテド 抗メチオニン化学療法における抗腫瘍薬としてのメチオニナーゼの使用
ATE361984T1 (de) 1992-12-04 2007-06-15 Me Medical Enzymes Ag Gentechnologisch hergestellte glutaminase und ihre verwendung in therapie
DK75593D0 (lt) 1993-06-25 1993-06-25 Novo Nordisk As
EP0776218A2 (en) * 1994-03-15 1997-06-04 Prizm Pharmaceuticals, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
JP3628333B2 (ja) 1995-09-21 2005-03-09 ジェネンテック インコーポレーテッド ヒト成長ホルモン変異体
CU22585A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
CA2315944A1 (en) * 1997-12-24 1999-07-08 Diatech Pty. Ltd. Bifunctional molecules
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6403312B1 (en) 1998-10-16 2002-06-11 Xencor Protein design automatic for protein libraries
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
JP4812167B2 (ja) 1999-02-12 2011-11-09 モレキュラー インサイト ファーマスーティカルズ インコーポレイテッド 薬物輸送用マトリックス、ならびにその作成方法および使用方法
ATE300952T1 (de) * 1999-12-09 2005-08-15 Chiron Corp Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
WO2001079469A2 (en) 2000-04-14 2001-10-25 University Of South Carolina Research Foundation Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses
US6967097B2 (en) 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
ATE545703T1 (de) * 2000-07-25 2012-03-15 Immunomedics Inc Multivalentes zielbindendes protein
AU2001294774A1 (en) * 2000-09-26 2002-04-08 The Regents Of The University Of California Characterization of phenylalanine ammonia-lyase (pal) gene in wounded lettuce
AU2002213843B2 (en) * 2000-11-10 2008-02-07 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
EP1476563B1 (en) 2002-02-26 2008-09-17 E.I. Du Pont De Nemours And Company Method for the recombination of genetic elements
AU2003246690B2 (en) * 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
CA2506026A1 (en) 2002-11-14 2004-05-27 The Scripps Research Institute Crystalline form of fatty acid amine hydrolase (faah)
RU2403262C2 (ru) * 2003-06-11 2010-11-10 Уайт Выделенный полипептид ib альфа гликопротеина тромбоцитов человека, слитый белок, молекула днк (варианты), экспрессирующий вектор (варианты), клетка (варианты), способ экспрессии полипептида, способ экспрессии слитого белка, фармацевтическая композиция (варианты), способ ингибирования прикрепления клетки крови к биологической ткани в биологической системе, способ ингибирования прикрепления белка к биологической ткани в биологической системе и способ лечения нарушения
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP1814984A2 (en) 2004-09-17 2007-08-08 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
EP1869174B1 (en) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
WO2008069958A2 (en) 2006-12-01 2008-06-12 The Salk Institute For Biological Studies Substrate switched ammonia lyases and mutases
US7560263B2 (en) 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof

Also Published As

Publication number Publication date
EP2152868A1 (en) 2010-02-17
CN101842482B (zh) 2014-10-22
ES2551315T3 (es) 2015-11-18
IL202132A0 (en) 2010-06-16
CA2687450A1 (en) 2008-12-18
CA2687450C (en) 2019-03-26
TWI418633B (zh) 2013-12-11
IL202132A (en) 2017-06-29
LUC00133I1 (lt) 2019-10-16
KR20150038753A (ko) 2015-04-08
HK1135141A1 (zh) 2010-05-28
LUC00133I2 (lt) 2020-07-16
AR110834A2 (es) 2019-05-08
HUE025784T2 (en) 2016-05-30
EA018443B1 (ru) 2013-08-30
CN101842482A (zh) 2010-09-22
LTPA2019517I1 (lt) 2019-10-25
JP5670183B2 (ja) 2015-02-18
EP2152868B1 (en) 2015-09-02
AR066716A1 (es) 2009-09-09
WO2008153776A8 (en) 2009-07-30
PE20090315A1 (es) 2009-03-19
MY151413A (en) 2014-05-30
CY2019039I2 (el) 2020-05-29
AU2008263190B2 (en) 2014-04-17
AU2008263190A1 (en) 2008-12-18
BRPI0811267A2 (pt) 2014-10-07
US7534595B2 (en) 2009-05-19
CY1116894T1 (el) 2017-04-05
MX2009012453A (es) 2010-01-25
BRPI0811267B8 (pt) 2021-05-25
NL301011I2 (nl) 2020-05-13
EP2657335A1 (en) 2013-10-30
EA200970980A1 (ru) 2010-04-30
US20080008695A1 (en) 2008-01-10
HUS1900049I1 (hu) 2019-11-28
NL301011I1 (nl) 2019-10-16
CY2019039I1 (el) 2020-05-29
CL2008001497A1 (es) 2009-01-09
TW200902052A (en) 2009-01-16
BRPI0811267B1 (pt) 2020-11-10
DK2152868T3 (en) 2015-11-16
HRP20151268T1 (hr) 2015-12-18
NO2019037I1 (no) 2019-10-16
PT2152868E (pt) 2015-11-13
WO2008153776A1 (en) 2008-12-18
KR20100024437A (ko) 2010-03-05
KR101603796B1 (ko) 2016-03-17
JP2010529835A (ja) 2010-09-02
SI2152868T1 (sl) 2015-12-31
PL2152868T3 (pl) 2016-01-29

Similar Documents

Publication Publication Date Title
LTPA2019517I1 (lt) Prokariotinės fenilalanino amonio liazės kompozicijos ir minėtų kompozicijų naudojimo būdai
IL257437B (en) Compositions of prokaryotic phenylalanine ammonia lyase variants and methods of using the compositions
LTPA2019003I1 (lt) Nauji junginiai ir kompozicijos ir jų panaudojimo būdai
LTPA2019006I1 (lt) Junginiai ir kompozicijos kaip proteinkinazės inhibitoriai
BRPI0820298A2 (pt) anticorpos anti-vegf composições e métodos
HRP20170347T1 (hr) Pripravci i postupci za uporabu za protutijela protiv sklerostina
IL204111A (en) Preparations of notch fusion proteins are individualized and used
LT2459715T (lt) Rekombinantinio adamts13 ir kitų baltymų gryninimo būdas ir jų kompozicijos
EP2483362A4 (en) Fluoropropene compounds and compositions and methods using same
EP2296879A4 (en) POLYMER MIXTURES AND METHOD FOR THEIR USE
BRPI0818003A2 (pt) inibidores de csf-1r, composições e métodos de uso
PL2356462T3 (pl) Kompozycje anty-CXCR1 oraz sposoby
BRPI0812159A2 (pt) inibidores de csf-1r, composições e métodos de uso
EP2285405A4 (en) VACCINE COMPOSITIONS AND METHODS
IL196920A0 (en) Compositions and methods using anti-csi antibodies to treat multiple myeloma
DE602008003698D1 (de) Globaler nagelschraubenhaltender Schraubendreher
EP2142926A4 (en) COMPOSITIONS AND METHODS OF DETECTION
IL207827A0 (en) Apoaequorin-containing compositions and methods of using same
GB0605247D0 (en) Compositions and methods for immunisation
DE602007001998D1 (de) Tonerzusammensetzungen und Verfahren
BRPI0922033A2 (pt) composições e métodos de uso de variantes de trombomodulina
EP2024461A4 (en) Self-Hydrogenating, Self-Crosslinking Guar Compositions and Methods
ZA200806601B (en) Cryoprotective compositions and methods of using same
IL192588A0 (en) Cryoprotective compositions and methods of using same
BRPI0916554A2 (pt) particulas de sulfato de amônio peletizadas